Description

Voglibose is an alpha-glucosidase inhibitor widely used in metabolic and diabetes-related research. It functions by delaying intestinal carbohydrate absorption, offering utility in studies on postprandial blood glucose regulation.

Litanging 0.2mg Voglibose Tablets provide consistent micro-dosing suitable for in vivo and in vitro exploration of insulin resistance, glucose metabolism, enzyme inhibition, and related pharmacological pathways.

?? This product is strictly intended for laboratory research use and is not authorized for human or veterinary consumption.

Voglibose Tablets Product Specifications

Voglibose Tablets Mechanism & Research Applications

Voglibose acts as a competitive inhibitor of intestinal alpha-glucosidase enzymes, delaying carbohydrate digestion and glucose absorption in the small intestine. In laboratory settings, this allows researchers to:

• Model postprandial hyperglycemia

• Investigate alpha-glucosidase inhibition mechanisms

• Compare effects with other antidiabetic agents (e.g., acarbose, miglitol)

• Explore impacts on glycemic variability and insulin sensitivity

• Analyze gut microbiota response to carbohydrate modulation

Voglibose Tablets Observed Effects in Research Models

In preclinical studies, voglibose has shown:

• Decreased postprandial blood glucose levels

• Minimal systemic absorption, acting locally in the gut

• Potential for reduced insulin secretion demand

• Low incidence of hypoglycemia in controlled settings

Safety & Handling

• Use Restriction: For laboratory research only

• PPE: Lab coat, gloves, safety glasses recommended

• Storage: Store in a sealed container below 25°C

• Disposal: Follow institutional guidelines for chemical disposal

Research Use Disclaimer

This product is intended strictly for laboratory research. It is not approved for therapeutic, diagnostic, or veterinary use. Misuse may result in legal or health risks. Always follow institutional safety protocols.